Mangoceuticals, Inc., operating under the MangoRx and PeachesRx brands, has reported significant initial success for its newly launched injectable testosterone replacement therapy program. The all-inclusive program is priced at $99 per month and includes doctor visits, consultations, lab work, and prescribed medication. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased by 336%, while customer acquisition costs declined by 54%.
The company attributes this growth to rising demand for convenient hormone health solutions delivered through its telehealth platform. MangoRx expects testosterone replacement therapy to serve as a primary growth driver alongside oral formulations, including PRIME by MangoRx powered by Kyzatrex. This expansion effort targets the global TRT market, which is estimated to reach approximately $2.1 billion to $2.2 billion by 2025.
MangoRx focuses on developing a variety of men's health and wellness products and services via a secure telemedicine platform. The company currently offers pharmaceutical-based treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Consumers can use MangoRx's telemedicine platform for a streamlined experience where prescription requests are reviewed by a licensed medical provider and, if approved, discreetly shipped to the patient's doorstep through a partner compounding pharmacy.
The implications of this announcement are multifaceted for the healthcare and telehealth industries. The dramatic sales growth and reduced acquisition costs suggest that affordable, comprehensive telehealth programs for men's health are meeting a significant market need. This could pressure competitors to offer similar value-based pricing models and accelerate the adoption of telehealth for chronic condition management. For consumers, it represents increased access to hormone therapy at a predictable, lower cost, potentially improving treatment adherence and outcomes.
As the company seeks to expand its presence in the growing global TRT market, its early success with this program may attract investor attention and validate the telehealth model for specialty medications. The broader impact includes normalizing men's health discussions and treatment via digital platforms, reducing stigma and geographical barriers to care. For more information about MangoRx's mission and products, visit https://www.MangoRx.com. The full press release is available at https://ibn.fm/T9ikw.
